RecruitingNCT04792892

ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer

Sponsor

Sahlgrenska University Hospital

Enrollment

600 participants

Start Date

Aug 1, 2021

Study Type

OBSERVATIONAL

Conditions

Anal Cancer

Summary

Anal cancer is a rare disease, but the incidence is rising. About 200 patients will get this type of cancer yearly in Sweden. Curative treatment includes chemotherapy and radiotherapy. The prognosis is good, but some patients will have recurrent or persistent disease after concluded chemo-radiotherapy and will then be offered salvage surgery. Some patients develop distant metastases that can be treated with good results. The aim of this study is to identify and describe functional outcome in patients diagnosed with anal cancer. We will study patients from diagnosis, try to identify early toxicity to treatment and then identify long-term morbidity.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking quality of life and functional outcomes in people who have been diagnosed with anal cancer (anal squamous cell carcinoma). Researchers want to understand how the disease and its treatment affect patients' daily lives, physical function, and emotional well-being over time. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with anal squamous cell carcinoma within the past 2 months - You are willing to give informed consent to participate **You may NOT be eligible if...** - You were diagnosed with anal cancer more than 2 months ago - You are under 18 - You are not willing to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.